MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?

被引:95
作者
Angelucci, Francesco [1 ,2 ]
Cechova, Katerina [1 ,2 ,3 ]
Valis, Martin [4 ]
Kuca, Kamil [5 ]
Zhang, Bing [6 ]
Hort, Jakub [1 ,2 ,3 ]
机构
[1] Charles Univ Prague, Dept Neurol, Memory Clin, Fac Med 2, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic
[4] Charles Univ Prague, Univ Hosp Hradec Kralove, Fac Med Hradec Kralove, Dept Neurol, Hradec Kralove, Czech Republic
[5] Univ Hradec Kralove, Dept Chem, Fac Sci, Hradec Kralove, Czech Republic
[6] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Radiol, Nanjing, Jiangsu, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
基金
中国国家自然科学基金;
关键词
microRNAs; Alzheimer's disease; biomarker; diagnosis; therapy; AMYLOID PRECURSOR PROTEIN; MOUSE MODEL; CIRCULATING MICRORNAS; PERIPHERAL BIOMARKERS; POTENTIAL BIOMARKER; CEREBROSPINAL-FLUID; MEMORY DEFICITS; BETA; EXPRESSION; NEURONS;
D O I
10.3389/fphar.2019.00665
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
MicroRNAs (miRNAs) are small non-coding nucleic acids able to post-transcriptionally regulate gene expression by binding to complementary sequences of target messenger RNA (mRNA). It has been estimated that at least 1% of the human genome encodes miRNA and every miRNA can regulate up to 200 mRNAs. These findings suggest that dysregulation of miRNA expression could be associated with several human pathological conditions including central neurological disorders. Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia in the elderly. The characteristic symptoms are a progressive loss of memory and other cognitive functions due to the impairment of particular types of neurons and synapses, leading to neuronal death. At present, the available symptomatic treatments can only slow down disease progression without stopping it. miRNAs are widely found within the nervous system where they are key regulators of functions such as neurite outgrowth, dendritic spine morphology, neuronal differentiation, and synaptic plasticity. This has been the clue for considering miRNAs crucial molecules to be studied in AD, and nowadays, dysfunction of miRNAs in AD is increasingly recognized. In this review, we summarized existing evidence about miRNAs as biomarkers or therapeutic agents. The field of miRNAs as biomarkers is more advanced in terms of human data, and it is likely that miRNAs will be used successfully in the near future. Given the huge number of miRNAs potentially involved in diagnostics, miRNA panels will be used for specific tasks such as the stage of the disease, the risk prediction, and disease progression. The field of miRNAs as therapeutics is rapidly developing, and it offers a huge variety of solutions. These include positive effects related to beta-amyloid or tau reduction, increased number of neurons, inhibition of apoptosis, protection of synapses, transformation of other cellular elements into missing/deficient neurons in AD, and so on. It is predictable that both areas of research will be carried forward. However, given the absence of an AD therapy able to stop or reverse the disease, it is desirable to accelerate research on miRNAs as therapeutic agents.
引用
收藏
页数:9
相关论文
共 98 条
  • [1] Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
    Adams, D.
    Gonzalez-Duarte, A.
    O'Riordan, W. D.
    Yang, C. -C.
    Ueda, M.
    Kristen, A. V.
    Tournev, I.
    Schmidt, H. H.
    Coelho, T.
    Berk, J. L.
    Lin, K. -P.
    Vita, G.
    Attarian, S.
    Plante-Bordeneuve, V.
    Mezei, M. M.
    Campistol, J. M.
    Buades, J.
    Brannagan, T. H., III
    Kim, B. J.
    Oh, J.
    Parman, Y.
    Sekijima, Y.
    Hawkins, P. N.
    Solomon, S. D.
    Polydefkis, M.
    Dyck, P. J.
    Gandhi, P. J.
    Goyal, S.
    Chen, J.
    Strahs, A. L.
    Nochur, S. V.
    Sweetser, M. T.
    Garg, P. P.
    Vaishnaw, A. K.
    Gollob, J. A.
    Suhr, O. B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 11 - 21
  • [2] A review of clinical treatment considerations of donepezil in severe Alzheimer's disease
    Adlimoghaddam, Aida
    Neuendorff, Melanie
    Roy, Banibrata
    Albensi, Benedict C.
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (10) : 876 - 888
  • [3] Alexandrov Peter N, 2012, Int J Biochem Mol Biol, V3, P365
  • [4] MiR-124 acts as a target for Alzheimer's disease by regulating BACE1
    An, Fengmao
    Gong, Guohua
    Wang, Yu
    Bian, Ming
    Yu, Lijun
    Wei, Chengxi
    [J]. ONCOTARGET, 2017, 8 (69) : 114065 - 114071
  • [5] [Anonymous], 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010803, DOI 10.1002/14651858.CD010803]
  • [6] Spontaneous Running Wheel Improves Cognitive Functions of Mouse Associated with miRNA Expressional Alteration in Hippocampus Following Traumatic Brain Injury
    Bao, Tian-hao
    Miao, Wei
    Han, Jian-hong
    Yin, Mei
    Yan, Yong
    Wang, Wei-wei
    Zhu, Yu-hong
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2014, 54 (04) : 622 - 629
  • [7] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [8] MicroRNA-298 and MicroRNA-328 Regulate Expression of Mouse β-Amyloid Precursor Protein-converting Enzyme 1
    Boissonneault, Vincent
    Plante, Isabelle
    Rivest, Serge
    Provost, Patrick
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (04) : 1971 - 1981
  • [9] MicroRNAs: Key Regulators in the Central Nervous System and Their Implication in Neurological Diseases
    Cao, Dan-Dan
    Li, Lu
    Chan, Wai-Yee
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06):
  • [10] Carmona Susana, 2018, Handb Clin Neurol, V148, P395, DOI 10.1016/B978-0-444-64076-5.00026-0